Who are Ketoconazole 2%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Monistat, Miconazole Nitrate 2%, Topical ketoconazole 2% cream, clotrimazole vaginal tablets, Topical Sertaconazole 2%, Nizoral®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ketoconazole-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Ketoconazole 2% — Competitive Intelligence Brief

Ketoconazole 2% (Ketoconazole 2%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Imidazole antifungal. Area: Infectious Disease / Dermatology.

marketed Imidazole antifungal Fungal cytochrome P450 (CYP51 / lanosterol 14α-demethylase) Infectious Disease / Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Ketoconazole 2% (Ketoconazole 2%) — University of California, Davis. Ketoconazole inhibits fungal cytochrome P450 enzymes, disrupting ergosterol synthesis in the fungal cell membrane and causing cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ketoconazole 2% TARGET	Ketoconazole 2%	University of California, Davis	marketed	Imidazole antifungal	Fungal cytochrome P450 (CYP51 / lanosterol 14α-demethylase)
Monistat	miconazole	Johnson & Johnson (Janssen)	marketed	Imidazole antifungal	7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6	1974-01-01
Miconazole Nitrate 2%	Miconazole Nitrate 2%	Aesculape CRO Belgium BV	marketed	Imidazole antifungal	Lanosterol 14α-demethylase (CYP51)
Topical ketoconazole 2% cream	Topical ketoconazole 2% cream	PAEC General Hospital, Islamabad	marketed	Imidazole antifungal	Fungal cytochrome P450 (CYP51 / lanosterol 14α-demethylase)
clotrimazole vaginal tablets	clotrimazole vaginal tablets	Peking University Shenzhen Hospital	marketed	Imidazole antifungal	Lanosterol 14α-demethylase (CYP51)
Topical Sertaconazole 2%	Topical Sertaconazole 2%	Jinnah Postgraduate Medical Centre	marketed	Imidazole antifungal	Lanosterol 14α-demethylase (CYP51)
Nizoral®	Nizoral®	Ache Laboratorios Farmaceuticos S.A.	marketed	Imidazole antifungal	Lanosterol 14α-demethylase (CYP51)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Imidazole antifungal class)

Galderma R&D · 2 drugs in this class
Bayer · 2 drugs in this class
AmDerma · 2 drugs in this class
Jinnah Postgraduate Medical Centre · 2 drugs in this class
Ache Laboratorios Farmaceuticos S.A. · 2 drugs in this class
Jamaica Hospital Medical Center · 1 drug in this class
Johnson & Johnson (Janssen) · 1 drug in this class
Laboratoire Innotech International · 1 drug in this class
PAEC General Hospital, Islamabad · 1 drug in this class
Peking University Shenzhen Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ketoconazole 2% — Competitive Intelligence Brief. https://druglandscape.com/ci/ketoconazole-2. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab